Prevalence of Metabolic Syndrome in Liver Transplant Recipients in Iran

S. J. Masoumi$^{1,2,3}$, Z. Mazloom$^{1,2,*}$, A. Rezaianzadeh$^4$, S. Nikeghbalian$^{5,6}$, S. A. Malek-Hosseini$^{5,6}$, H. Salahi$^{5,6}$

$^1$School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
$^2$Nutrition and Food Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
$^3$Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
$^4$Department of Epidemiology, Shiraz University of Medical Sciences, Shiraz, Iran
$^5$Department of Surgery, Shiraz University of Medical Sciences, Shiraz, Iran
$^6$Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

ABSTRACT

Background: Metabolic syndrome (MetSx) is common among liver transplant recipients. It contributes to morbidity and mortality.

Objective: To determine the prevalence of MetSx in patients undergoing liver transplantation (LTx) in Iran.

Methods: 202 liver transplant recipients of both sexes completed this study. Relevant information including age, sex, the underlying disease, systolic and diastolic blood pressure, waist circumference, fasting serum levels of blood sugar (FBS), triglyceride (TG), and HDL-cholesterol were measured. The prevalence of MetSx was evaluated at 1, 3, 6, 9, and 12 months after LTx.

Results: The prevalence of MetSx was 36.6% after 1 month that decreased to 28.2% after 12 months of follow-up. The lowest prevalence of MetSx (27.7%) was observed 9 months after LTx. Our data showed a decrease in TG and an increase in HDL-C level and no significant changes in blood pressure, waist circumference and FBS during the study period.

Conclusion: The prevalence of MetSx after LTx is high when compared to the normal population. It seems that a change in diet after transplantation may affect the prevalence of MetSx.

KEYWORDS: Metabolic syndrome; Transplant recipients; Hyperglycemia; Hyperlipidemias; Liver transplantation; Prevalence

INTRODUCTION

Metabolic syndrome (MetSx) is a compilation of metabolic manifestations of obesity defined by a combination of increased abdominal girth, hypertension, hyperglycemia, and dyslipidemia [1, 2]. This disorder represents a number of cardiometabolic risk determinants including central obesity, insulin resistance, hypertension, and dyslipidemia [3, 4]. MetSx is one of the most common complications after liver transplantation (LTx). Obesity and MetSx are affecting almost every aspect of LTx including the type and incidence of post-LTx complications [5]. Several studies showed that MetSx existed in 40%-58% of patients followed for six months after LTx [6, 7].

Primary defects in energy balance that cause obesity (visceral adiposity in particular) are sufficient to drive all aspects of the syndrome. Increased free fatty acids and accumulation of
Fat in certain organs are mediators of obesity and insulin resistance. Obesity also leads to proinflammatory and prothrombotic states that potentiate atherosclerosis. Pathways leading directly from adiposity to the genesis of dyslipidemia and hypertension have been elucidated and reported [8]. Recent knowledge implies a role for fat-derived “adipokines” including TNF and adiponectin, as pathogenic contributors or protective factors [8].

The incidence of new-onset diabetes mellitus (NOD) after orthotopic LTx in adult transplant recipients reported to be 25.8% [9], while MetSx reported to be 51.9% after LTx [7]. In another study, it was shown that the absolute prevalence of diabetes mellitus (DM) rose from about 15% prior to LTx to 30%–40% after LTx [5]. Kuo and his colleagues reported that the NOD after LTx occurred in 26% of patients without documented diabetes before transplantation in the United Network for Organ Sharing database [10]. Considering the other components of MetSx, dyslipidemia has been detected in approximately 50%–70% of patients after LTx [11]. Hypertension also increased from 15% in pre-transplantation patients to 60%–70% in those post-transplantation [5]. Obesity and increased waist circumference were also seen commonly after LTx [12, 13]. The greatest weight gains occurred within the first six months after transplantation [5]. Needless to say, the impact of MetSx in LTx recipients is substantial, and it may cause graft rejection after transplantation. The present study was undertaken to determine the prevalence of MetSx in patients undergoing LTx in Iran.

**PATIENTS AND METHODS**

**Patients**

Two-hundreds and two adult LTx recipients from Shiraz Organ Transplantation Center in Nemazee Hospital affiliated to Shiraz University of Medical Sciences, Shiraz, Iran, who had no previous history of acute cardiovascular diseases (CVD) or cancer before LTx, were enrolled in this study. Patients who had recurrence of cirrhosis or chronic ascites and pregnant women were excluded from the study. The study was approved by the Ethics Committee of Shiraz University of Medical Sciences, Shiraz, Iran. A written informed consent was obtained from each patient. All clinical evaluations were performed at Organ Transplantation Center; all tests were done at Nemazee Hospital.

| Categories         | n (%)       |
|--------------------|-------------|
| Sex                |             |
| Male               | 126 (62.4)  |
| Female             | 76 (37.6)   |
| DM                 |             |
| No                 | 196 (97.0)  |
| Yes                | 6 (3.0)     |
| HT                 |             |
| No                 | 200 (99.0)  |
| Yes                | 2 (1.0)     |
| HL                 |             |
| No                 | 199 (98.5)  |
| Yes                | 3 (1.5)     |
| CVD                |             |
| No                 | 202 (100)   |
| Yes                | 0 (0)       |
| RD                 |             |
| No                 | 201 (99.5)  |
| Yes                | 1 (0.5)     |
| Cancer             |             |
| No                 | 202 (100)   |
| Yes                | 0 (0)       |

*DM: Diabetes mellitus; HT: Hypertension; HL: Hyperlipidemia; CVD: Cardiovascular diseases; RD: Renal diseases

| Variables | 1st | 3rd | 6th | 9th | 12th |
|-----------|-----|-----|-----|-----|------|
| FBS (mg/dL) | 110.2±53.7 | 96.4±28.5 | 100.2±36.6 | 100.5±40.46 | 102.5±42.4 |
| TG (mg/dL)  | 188.6±77.2 | 167.5±76.9 | 155.2±73.0 | 142.0±63.9 | 136.5±67.2 |
| HDL-C (mg/dL) | 40.6±12.0 | 44.4±11.9 | 44.8±12.1 | 43.6±11.7 | 43.6±12.9 |

FBS: Fasting blood sugar; TG: Triglyceride; HDL-C: High-density lipoprotein cholesterol
Patients were followed for 12 months. The National Heart, Lung, and Blood Institute/American Heart Association (NHLBI/AHA) clinical identification of MetSx was considered for the diagnosis of MetSx [14]. The diagnosis depended on observation of at least three of the following criteria: (i) waist circumference in women >88 cm and in men >102 cm; (ii) fasting blood sugar (FBS) >100 mg/dL; (iii) blood pressure (BP): systolic >130 mm Hg, diastolic >85 mm Hg; (iv) high-density lipoprotein cholesterol (HDL-C) in women <50 mg/dL and in men <40 mg/dL; and (v) triglyceride (TG) level >150 mg/dL. The demographic information and medical history were also recorded for each patient.

Clinical Evaluations
All clinical evaluations were performed at Organ Transplantation Center of Nemazee Hospital. The follow up was monthly for the first six months, and then at 9th and 12th months. Waist circumference was measured at the umbilicus level with the patient standing as an index of central fat accumulation. BP was also determined for each patient.

Biochemical Analyses
Blood samples were drawn from each subject after an overnight fasting. Serum samples were stored at -80 °C until analyses. Fasting plasma glucose was measured on the day of blood collection by the enzymatic colorimetric method using glucose oxidase. Serum TG concentration was measured by commercially available enzymatic reagents adapted to an autoanalyzer. HDL-C was measured after precipitation of the apolipoprotein B-containing lipoproteins with phosphotungstic acid.

Statistical Analysis
Statistical analyses were performed by SPSS® for Windows® ver 20.0 (SPSS Inc., Chicago, IL, USA). The results are presented as mean±SD.

RESULTS
The baseline characteristics data and underlying diseases/disorders of the LTx recipients are presented in Table 1. The male to female ratio in our study was nearly 2:1 (126 male and 76 female patients). The most frequent underlying diseases in LTx patients were DM and hyperlipidemia (six and three patients, respectively), where hypertension and renal diseases were the least (two and one patient, respectively). Analyses of the biochemical variables, including FBS, TG, and HDL-C level are presented in Table 2. TG concentration decreased from 188.6±77.2 mg/dL on the 1st month to 136.5±67.2 mg/dL at the 12th month. HDL-C also increased considerably from 40.6±12.0 mg/dL at the 1st month to 43.6±12.9 mg/dL at the 12th month. Waist circumference and systolic and diastolic blood pressure did not change significantly during the 12th month of the study (Table 3). The highest prevalence of MetSx (36.6%; 95% CI: 30.0%–43.3%) was recorded at the 1st month after transplantation where the lowest prevalence (27.7%; 95% CI: 21.5%–33.9%) was at the 9th month (Fig 1).

DISCUSSION
MetSx is common among LTx recipients. Although the cause of post-LTx MetSx is not clear, post-transplantation weight gain together with the side effects of immunosuppressive drugs could play a role in induction of MetSx.
This study assessed the prevalence of MetSx after LTx in patients hospitalized in the Organ Transplantation Center, Shiraz, Iran. Although, a slight tendency to decline in the prevalence of MetSx was seen in LTx patients during the study period, this decline was not sharp. A reduction in TG and an increase in HDL-C level were also seen in the transplant recipients. However, no changes were noticed in the BP, waist circumference and FBS during the study period.

Considering the five metabolic components of MetSx—obesity, hyperglycemia, hypertriglyceridemia, hypertension, and low HDL-C level—we found obesity in one-third to one-half of patients with normal weight at the time of LTx [13]. Hanouneh, et al, in their study evaluated the underlying mechanisms of this phenomenon and demonstrate that steroids and immunosuppressive drugs, which are commonly used after LTx, are responsible for this increase [12]. As much as the obesity affects the incidence of DM, hyperlipidemia, and hypertension (other components of MetSx), there has been a lot of focus on NOD after LTx in recent years.

In a study performed by Kuo, et al, the NOD-related risk factors were evaluated. It was found that old age (more than 60 years), body mass index (BMI) more than 25 kg/m², HCV infection, cirrhosis, and use of methylprednisolone, tacrolimus (TAC), and steroids in recipients and a history of diabetes in donors are independent risk factors for the development of NOD after LTx [16]. Liver vagotomy, which occurred during LTx, and immunosuppressive drugs can induce insulin resistance and development of NOD [5].

The prevalence of MetSx among Iranian population is about 30% [15]. Clearly, that prevalence of MetSx can be changed in response to diseases affecting liver [16]. Hanouneh, et al, reported a 50% rate of MetSx in their patients after LTx [17]. This value was reported as 58% by Laryea, et al [6]. Francioso, et al, and Sprinzl, et al, reported the prevalence of post-LTx MetSx to be 43% and 45%, respectively [18, 19]; the prevalence in our study was 36.1% six months post-LTx. Comparing the findings of this study with the Canadian and Italian studies, revealed that the prevalence of MetSx is lower in Iran. This may be attributed to variations in the studied population, lifestyle and the selected criteria. It seems that the Iranian proposed criteria adopted by Iranian National Committee of Obesity would be better diagnostic criteria for evaluation of MetSx among Iranian population [20]. In another study, it was shown that the clinical and biochemical features of MetSx were independent from etiology of pre-LTx liver disease [21]. However, in a recent study by De Luca and his colleagues, it was reported that patients transplanted for etiologies other than non-alcoholic steatohepatitis, typically gained weight and often developed DM, hypertension and dyslipidemia as a consequence of immunosuppressive therapy and a resultant MetSx [22].

Sprinzl and his colleagues reported the new-onset and total prevalence of MetSx after LTx that were 32.9% and 45.3%, respectively in their study [23]. MetSx was also reported in 51.9% of patients after LTx by Laish and his colleagues in 2011 [7]. Although the prevalence of MetSx in these studies were higher than what we detected in the present study (36.6%), this could be due to differences in the underlying diseases and the variation in patients’ life style, needless to say that in spite...
of the differences, the prevalence of MetSx in our patients was in line with many other studies [6, 18, 23] that demonstrated that approximately one-third of the patients suffered from MetSx after LTx. An interesting finding of this study was the decline in the prevalence of MetSx after 12 months of LTx; other studies did not report any decrease during their follow up [2-4]. These differences may be due to different definitive criteria for evaluation of MetSx and its components.

DM, hypertriglyceridemia, hypertension, and low levels of HDL-C were noticed in patients with MetSx in the present study. Similar findings were also reported in previous studies for DM [25-31], dyslipidemia [29, 30, 32-34], abdominal obesity [29, 30, 34], and hypertension [29, 30, 33, 35] as well.

A clear decrease in TG and an obvious increase in HDL-C level were observed during the 12 months of follow up. Liver is the main organ where lipid synthesis and degradation are occurred. Also, it involves fat excretion by bile acid synthesis. Any changes in its normal function can thus disturb the lipid balance and alter the lipid profile. Our findings could be attributed to an enhanced lipid turnover and body fluid re-compensation during hepatic recovery, but it might also be explained by a post-interventional catabolic phase as well [23].

In conclusion, the prevalence of MetSx after LTx is still higher compared to the normal population previously reported in Iran and other countries. It seems that a change in diet and physical activity of LTx patients may affect the prevalence of MetSx. There is a need for further interventional research on these patients to decrease the prevalence of MetSx.

ACKNOWLEDGMENTS

The authors would like to thank Shiraz University of Medical Sciences for financial support and Mr. Siavash Gholami, Mrs. Parisa Janghorban, Goli Mehrdad, Najmeh Hosseini and Zahra Izedi for their assistance in patients’ collection and data gathering. Also we thank Dr. Babak Shirazi for his cooperation with laboratory tests and Dr. Davood Mehrabani for assistance in writing the manuscript.

CONFLICTS OF INTEREST: None declared.

REFERENCES

1. Grundy SM, Becker D, Clark LT, et al. NIH, third report of the National Cholesterol Education Program expert panel on detection, evaluation, and treatment of high blood pressure in adults (Adult Treatment Panel III). In: Bethesda M, ed. National Institutes of Health, 2001.

2. Cauchi F, Fuks D, Le Bian AZ, et al. Metabolic syndrome and non-alcoholic fatty liver disease in liver surgery: The new scourges? World Journal of Hepatology 2014;6:306-14.

3. Reaven G. Metabolic syndrome: Pathophysiology and implications for management of cardiovascular disease. Circulation 2002;106:286-8.

4. Kassi E, Pervanidou P, Kaltas G, Chrousos G. Metabolic syndrome: definitions and controversies. BMC Medicine 2011;9:48-60.

5. Watt KDS, Charlton MR. Metabolic syndrome and liver transplantation: A review and guide to management. Journal of Hepatology 2010;53:199-206.

6. Laryea M, Watt KD, Molinari M, et al. Metabolic syndrome in liver transplant recipients: prevalence and association with cardiovascular events. Liver Transpl 2007;13:1109-14.

7. Laish I, Braun M, Mor E, et al. Metabolic syndrome in liver transplant recipients: Prevalence, risk factors, and association with cardiovascular events. Liver Transplantation 2011;17:15-22.

8. Moller DE, Kaufman KD. Metabolic syndrome: a new view of some familiar transplant risks. Annu Rev Med 2006;56:45-62.

9. Dehghani SM, Taghavi SA, Imanieh MH, et al. Diabetes mellitus after liver transplantation in Iranian patients. Indian J Gastroenterology 2008;27:83-4.

10. Kuo HT, Sampaio MS, Ye X, et al. Risk factors for new-onset diabetes mellitus in adult liver transplant recipients, an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing database. Transplantation 2010;89:1134-40.

11. Pfitzmann R, Nussler NC, Hippler-Benschmidt M, et al. Long-term results after liver transplantation. Transpl Int 2008;21:234-46.

12. Richards J, Gunson B, Johnson J, Neuberger J. Weight gain and obesity after liver transplantation. Transplant International 2005;18:461-6.

13. Wawrzynowicz-Syczewska M, Karpinska E, Jurczyk
K, et al. Risk factors and dynamics of weight gain in patients after liver transplantation. *Annals of Transplantation* 2009;14:45-50.

14. Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation* 2009;120:1640-5.

15. Hadaegh F, Zabetian A, Harati H, Azizi F. Metabolic syndrome in normal-weight Iranian adults. *Annals of Saudi Medicine* 2007;27:18-24.

16. Chen SH, He F, Zhou HL, et al. Relationship between nonalcoholic fatty liver disease and metabolic syndrome. *Journal of Digestive Diseases* 2011;12:125-30.

17. Hanouneh IA, Feldstein AE, McCullough AJ, et al. The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. *Liver Transpl* 2008;14:1287-93.

18. Bianchi G, Marchesini G, Marzocchi R, et al. Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. *Liver Transpl Int* 2008;14:1648-54.

19. Francioso S, Angelico F, Baiocchi L, et al. High prevalence of metabolic syndrome and long-term survival after liver transplantation. *J Hepatol* 2008;48:S82.

20. Azizi F, Hadaegh F, Khalili D, et al. Appropriate definition of metabolic syndrome among Iranian adults: Report of the Iranian National Committee of Obesity. *Archives of Iranian Medicine* 2010;13:426-8.

21. Bianchi G, Marchesini G, Marzocchi R, et al. Metabolic syndrome in liver transplantation: Relation to etiology and immunosuppression. *Liver Transplantation* 2008;14:1648-54.

22. De Luca L, Westbrook R, Tschatzis EA. Metabolic and cardiovascular complications in the liver transplant recipient. *Annals of Gastroenterology* 2015;28:1-11.

23. Sprinzl MF, Weinmann A, Lohse N, et al. Metabolic syndrome and its association with fatty liver disease after orthotopic liver transplantation. *Transplant International* 2013;26:67-74.

24. Lunati ME, Grancini V, Agnelli F, et al. Metabolic syndrome after liver transplantation: Short-term prevalence and pre-and post-operative risk factors. *Digestive and Liver Disease* 2013;45:833-9.

25. Munoz SJ, Deems RO, Moritz MJ, et al. Hyperlipidemia and obesity after orthotopic liver transplantation. *Transplant Proc* 1991;23:1480-3.

26. Everhart JE, Lombardero M, Lake JR, et al. Weight change and obesity after liver transplantation: incidence and risk factors. *Liver Transpl Surg* 1998;4:285-96.

27. Gisbert C, Prieto M, Berenguer M, et al. Hyperlipidemia in liver transplant recipients: prevalence and risk factors. *Liver Transpl Surg* 1997;3:416-22.

28. Contos MJ, Cales W, Sterling RK, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. *Liver Transpl* 2001;7:363-73.

29. Lim LG, Cheng CL, Wee A, et al. Prevalence and clinical associations of posttransplant fatty liver disease. *Liver Int* 2007;27:76-80.

30. Seo S, Maganti K, Khehra M, et al. De novo non-alcoholic fatty liver disease after liver transplantation. *Liver Transpl* 2007;13:844-7.

31. Manzarbeitia C, Reich DJ, Rothstein KD, et al. Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipients. *Liver Transpl* 2001;7:93-9.

32. John P, Thuluvath P. Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus. *Liver Transpl* 2002;8:708-13.

33. Navasa M, Bustamante J, Marroni C, et al. Diabetes mellitus after liver transplantation: prevalence and predictive factors. *J Hepatol* 1996;25:64-71.

34. Tcuehe SG. Diabetes mellitus after liver transplant: new etiologic clues and cornerstones for understanding. *Transplant Proc* 2003;35.

35. Bigam DL, Pennington JJ, Carpentier A, et al. Hepatitis C-related cirrhosis: a predictor of diabetes after liver transplantation. *Hepatology* 2000;32:87-90.